August 1, 2014

Contact:
Corporate Communications,
Astellas Pharma Inc.
TEL +81-3-3244-3201

Financial Results of Astellas for the First Three Months of FY2014 (IFRS)

Japan, August 1, 2014 – Astellas Pharma Inc. (hereinafter referred to as "the Company") today announced the financial results for the first three months of the fiscal year 2014 (FY2014) ending March 31, 2015.

Consolidated financial results for the first three months of FY2014 (April 1, 2014 – June 30, 2014) (core basis)

(Millions of yen)

	First three months of FY2013	**First three months of FY2014**	Change (%)
Sales	269,505	**295,157**	+25,652 (+9.5%)
Core operating profit	44,507	**65,976**	+21,469 (+48.2%)
Core profit for the period	31,750	**46,409**	+14,659 (+46.2%)
Core earnings per share (yen)	14.07	**20.90**	+6.83 (+48.5%)

Cautionary statement regarding forward-looking information

This press release includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Consequently, any statements herein do not constitute assurances regarding actual results by the Company. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the Company to market existing and new product effectively, interruptions in production, infringement of the Company's intellectual property rights and the adverse outcome of material litigation.

1. Qualitative information on consolidated financial results for the first three months of FY2014

(1) Information on business performance

The Company discloses financial results on a core basis as an indicator of its recurring profitability. Certain items reported in financial results on a full basis that are deemed to be non-recurring items by the Company are excluded as non-core items from these financial results on a core basis. These adjusted items include impairment losses, gain (loss) on sales of property, plant and equipment, restructuring costs, loss on disaster, a large amount of losses on compensation or settlement of litigations and other legal disputes, and other items that the Company judges should be excluded. A reconciliation table between results on a full basis and results on a core basis is provided on page 21 of the "Supplement Documents for Results 1Q/FY2014."

Consolidated financial results (core basis) in the first three months of FY 2014 showed increases in sales, core operating profit and core profit for the period, as follows.

Consolidated financial results (core basis)

(Millions of yen)

	First three months of FY2013	**First three months of FY2014**	Change (%)
Sales	269,505	**295,157**	+25,652 (+9.5%)
Core operating profit	44,507	**65,976**	+21,469 (+48.2%)
Core profit for the period	31,750	**46,409**	+14,659 (+46.2%)
Core earnings per share (yen)	14.07	**20.90**	+6.83 (+48.5%)

(Note) The Company conducted a stock split of common stock at a ratio of 5 for 1 with an effective date of April 1, 2014. Core earnings per share is calculated based on the number of issued shares after the stock split (excluding treasury shares) on the assumption that the stock split was conducted at the beginning of FY2013.

Research and development (R&D) expenses

(Millions of yen)

	First three months of FY2013	**First three months of FY2014**	Change
R&D expenses	44,105	**47,643**	+3,538

Impact of exchange rate on financial results

The exchange rates for the yen in the first three months of FY2014 are shown in the table below. The resulting impacts were a ¥10.0 billion increase in sales and an ¥8.3 billion increase in core operating profit.

Average rate	First three months of FY2013	**First three months of FY2014**	Change
¥/US$	¥99	**¥102**	¥3 (Weakening of yen)
¥/€	¥129	**¥140**	¥11 (Weakening of yen)

Change from beginning to end of period	As of June 30, 2013	**As of June 30, 2014**
¥/US$	¥5 (Weakening of yen)	**¥2 (Strengthening of yen)**
¥/€	¥8 (Weakening of yen)	**¥3 (Strengthening of yen)**

Sales

Consolidated sales in the first three months of FY2014 increased by 9.5% compared to those in the corresponding period of the previous fiscal year ("year-on-year") to ¥295.2 billion.

- In addition to a new product, XTANDI for the treatment of prostate cancer, sales of overactive bladder (OAB) treatments Vesicare and Betanis / Myrbetriq / BETMIGA grew. Sales of Prograf, an immunosuppressant increased partly due to the foreign exchange rate impact.

Sales by region

*Sales by region calculated according to locations of sellers.

<Japan>

Sales in Japan decreased by 9.5% year-on-year to ¥112.8 billion. Sales in the Japanese market decreased by 9.9% year-on-year to ¥109.0 billion. The impacts of NHI drug price revision enforced in April 2014, generics and other factors caused overall sales to decline year-on-year.

- Betanis, Cimzia for the treatment of adult patients with rheumatoid arthritis and other products expanded steadily in sales. In addition, there were contributions from sales of the selective SGLT2 inhibitor Suglat and XTANDI, which were launched in April and May 2014, respectively.
- On the other hand, sales of products declined, including Lipitor for the treatment of hypercholesterolemia, Seroquel for the treatment of schizophrenia, Myslee for the treatment of insomnia, and Gaster for the treatment of peptic ulcer and gastritis, mainly due to the impacts of NHI drug price revision and generics.
- Furthermore, there were decreases in sales of products including the anti-inflammatory and anti-pain drug Celecox, Symbicort for the treatment of bronchial asthma and Bonoteo for the treatment of osteoporosis reflecting temporary fluctuations in supply and demand

conditions before and after the consumption tax hike implemented in April 2014.

<Outside of Japan>

Sales in the Americas increased by 21.9% year-on-year to ¥83.8 billion. The sales on a U.S. dollar basis increased by 17.8% year-on-year to US$821 million.

- Sales of XTANDI and overall sales of OAB treatments VESIcare and Myrbetriq grew.
- In addition, there were increases in sales of Prograf and income from anticancer drug Tarceva and others.
- Overall sales of the pharmacologic stress agents Adenoscan and Lexiscan decreased.

Sales in Europe* increased by 32.9% year-on-year to ¥82.4 billion. The sales on a euro basis increased by 22.3% year-on-year to €589 million.

* This category includes sales from the Middle and Near East, and Africa in addition to Europe.

- In addition to XTANDI and overall OAB treatments Vesicare and BETMIGA, sales of the Candin-type antifungal agent MYCAMINE and others grew.
- Furthermore, sales of Prograf increased partly due to the foreign exchange rate impact.

Sales in Asia and Oceania increased by 15.1% year-on-year to ¥16.1 billion.

- Products such as Prograf, Harnal and Vesicare showed growth in sales, resulting in an increase in revenue.

Core operating profit / Core profit for the period

- The increase in sales and a fall in the cost-to-sales ratio resulted in a gross profit of ¥219.2 billion, up 16.4% year-on-year. The cost-to-sales ratio fell 4.4 percentage points year-on-year to 25.7%, owing to changes in product mix and other factors.
- Selling, general and administrative expenses increased by 6.3% year-on-year to ¥96.9 billion, which in addition to the foreign exchange rate impact, was partly due to increased expenditures for co-promotion of XTANDI in the US.
- Research and development (R&D) expenses were ¥47.6 billion, up 8.0% year-on-year, which in addition to the foreign exchange rate impact, was partly due to increased expenses related to progress of development projects. The R&D cost-to-sales ratio was down 0.2 percentage points year-on-year to 16.1%.
- Amortisation of intangible assets was ¥8.9 billion, up 0.8% year-on-year.

As a result of the above, core operating profit increased by 48.2% year-on-year to ¥66.0 billion. Core profit for the period increased by 46.2% to ¥46.4 billion. Core earnings per share increased by 48.5% to ¥20.90.

<Consolidated financial results (full basis)>

Consolidated financial results on a full basis in the first three months of FY2014 are shown in the table below. Sales, operating profit, profit before tax and profit for the period increased.

Items excluded from core results including impairment losses on other intangible assets and restructuring costs at a total of ¥18.1 billion (compared to ¥18.2 billion in the same period of the previous fiscal year) were recorded in "other expense." The details of the non-core items that are excluded from core results are provided on page 21 of the "Supplement Documents for Results 1Q/FY2014."

Consolidated financial results (full basis)

(Millions of yen)

	First three months of FY2013	**First three months of FY2014**	Change (%)
Sales	269,505	**295,157**	+25,652 (+9.5%)
Operating profit	26,410	**50,565**	+24,155 (+91.5%)
Profit before tax	26,380	**50,278**	+23,898 (+90.6%)
Profit for the period	19,827	**35,861**	+16,034 (+80.9%)
Earnings per share (yen)	8.79	**16.15**	+7.36 (+83.7%)
Comprehensive income	56,040	**22,519**	-33,520 (-59.8%)

(Note) The Company conducted a stock split of common stock at a ratio of 5 for 1 with an effective date of April 1, 2014. Earnings per share is calculated based on the number of issued shares after the stock split (excluding treasury shares) on the assumption that the stock split was conducted at the beginning of FY2013.

(2) Information on financial position

1) Assets, equity and liabilities

An overview of the consolidated statement of financial position as of June 30, 2014 and the main changes from the end of the previous fiscal year are shown below.

Assets

Total assets as of June 30, 2014 saw a decrease of ¥36.8 billion compared to the end of the previous fiscal year to ¥1,616.3 billion.

<Non-current assets> ¥725.2 billion (a decrease of ¥14.6 billion)

- Other intangible assets decreased by ¥11.1 billion compared to the end of the previous fiscal year to ¥269.0 billion.

<Current assets> ¥891.1 billion (a decrease of ¥22.2 billion)

- Cash and cash equivalents decreased by ¥18.4 billion compared to the end of the previous fiscal year to ¥373.0 billion.

Equity

Total equity as of June 30, 2014 saw a decrease of ¥38.6 billion compared to the end of the previous fiscal year to ¥1,229.8 billion, making the ratio of owners' equity to gross assets 76.1%.

- While profit for the period stood at ¥35.9 billion, the Company paid ¥31.2 billion of dividends of surplus and acquired ¥30.0 billion of own shares.
- Cancellation of treasury shares totaling ¥25.4 billion (25 million shares) was carried out on May 30, 2014.
- In addition, the effect of foreign currency translation adjustments reduced equity by ¥12.8 billion.

Liabilities

Total liabilities increased by ¥1.8 billion compared to the end of the previous fiscal year to ¥386.4 billion.

<Non-current liabilities> ¥44.7 billion (an increase of ¥0.8 billion)
<Current liabilities> ¥341.7 billion (an increase of ¥1.0 billion)

2) Cash flow

Cash flows from operating activities

Net cash flows from operating activities increased year-on-year by ¥15.0 billion to ¥60.7 billion.

- Income tax paid was ¥22.4 billion, an increase in outflow of ¥12.2 billion year-on-year.

Cash flows from investing activities

Net cash flows used in investing activities was ¥12.1 billion, a decrease in outflow of ¥1.5 billion year-on-year.

- Purchases of property, plant and equipment used cash of ¥5.3 billion and purchase of intangible assets used cash of ¥11.5 billion.

Cash flows from financing activities

Net cash flows used in financing activities was ¥61.4 billion, an increase in outflow of ¥32.0 billion year-on-year.

- Dividends paid totaled ¥31.2 billion, an increase in outflow of ¥1.9 billion year-on year. Other outflow included cash of ¥30.0 billion used for the acquisition of own shares.

As a result of the above, cash and cash equivalents totaled ¥373.0 billion as of June 30, 2014, a decrease of ¥18.4 billion compared to the end of the previous fiscal year.

(3) Information on consolidated business forecasts for FY2014 and other forward-looking statements

The Company's business forecasts for FY2014 are presented on a core basis.

The consolidated full-year business forecasts (core basis) for the fiscal year ending March 31, 2015 (FY2014) are shown below. No changes have been made to the forecasts announced in May 2014.

Consolidated full-year business forecasts (core basis)

(Millions of yen)

	FY2013 Full-year results	**FY2014 Full-year forecasts**	Change (%)
Sales	1,139,909	**1,192,000**	+52,091 (+4.6%)
Core operating profit	186,253	**208,000**	+21,747 (+11.7%)
Core profit for the year	132,796	**154,000**	+21,204 (+16.0%)
Core earnings per share (yen)	59.11	**69.65**	+10.54 (+17.8%)

(Note) The Company conducted a stock split of common stock at a ratio of 5 for 1 with an effective date of April 1, 2014. Core earnings per share is calculated based on the number of issued shares after the stock split (excluding treasury shares) on the assumption that the stock split was conducted at the beginning of FY2013. In addition, acquisitions of own shares carried out from May 13 to June 23, 2014 are reflected in the figures.

Expected exchange rate for

FY2014	**¥100/US$**	**¥140/€**
FY2013 (Result)	¥100/US$	¥134/€

2. Matters Related to Summary Information (Notes)

(1) Changes in Accounting Policies and Accounting Estimates

The significant accounting policies adopted for the Group's condensed interim consolidated financial statements for the three months ended 30 June 2014 are the same as those applied for its consolidated financial statements for the fiscal year ended 31 March 2014, except for the new standards listed below.

The Group calculated income tax expense for the three months ended 30 June 2014 based on the estimated average annual effective tax rate.

The following accounting standards and interpretations are newly applied by the Group from the three months ended 30 June 2014 in compliance with each transitional provision. These standards and interpretations do not have a material impact on the Group's condensed interim consolidated financial statements.

IFRS		Summary of new standards and amendments
IAS 32	Financial Instruments: Presentation	Offsetting financial assets and financial liabilities
IAS 36	Impairment of Assets	Disclosures related to recoverable amount of non-financial assets
IFRS 10	Consolidated Financial Statements	Establishment of accounting treatment for entities meeting new definition of investment entity
IFRS 12	Disclosure of Interests in Other Entities	Additional disclosure requirements for newly defined investment entities
IFRIC 21	Levies	Clarification of recognition of liabilities for levies

3. Condensed Interim Consolidated Financial Statements

(1) Condensed Interim Consolidated Statements of Income

（Millions of Yen）

	Three months ended 30 June 2013	Three months ended 30 June 2014
Sales	269,505	295,157
Cost of sales	(81,181)	(75,983)
Gross profit	188,324	219,174
Selling, general and administrative expenses	(91,141)	(96,908)
Research and development expenses	(44,105)	(47,643)
Amortisation of intangible assets	(8,792)	(8,864)
Share of profits of associates and joint ventures	221	218
Other income	121	2,700
Other expense	(18,218)	(18,111)
Operating profit	26,410	50,565
Finance income	644	1,825
Finance expense	(674)	(2,112)
Profit before tax	26,380	50,278
Income tax expense	(6,553)	(14,417)
Profit for the period	19,827	35,861
Profit attributable to:		
Owners of the parent	19,827	35,861
Earnings per share		
Basic（Yen）	8.79	16.15
Diluted（Yen）	8.78	16.13

(2) Condensed Interim Consolidated Statements of Comprehensive Income

(Millions of Yen)

	Three months ended 30 June 2013	Three months ended 30 June 2014
Profit for the period	19,827	35,861
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Remeasurements of defined benefit plans	1,942	537
Total items that will not be reclassified subsequently to profit or loss	1,942	537
Items that may be reclassified subsequently to profit or loss		
Foreign currency translation adjustments	32,152	(12,792)
Fair value movements on available-for-sale financial assets	2,119	(1,087)
Total items that may be reclassified subsequently to profit or loss	34,271	(13,879)
Other comprehensive income, net of tax	36,213	(13,342)
Total comprehensive income	56,040	22,519
Total comprehensive income attributable to:		
Owners of the parent	56,040	22,519

(3) Condensed Interim Consolidated Statements of Financial Position

(Millions of Yen)

	As of 31 March 2014	As of 30 June 2014
Assets		
Non-current assets		
Property, plant and equipment	191,451	188,223
Goodwill	116,766	114,996
Other intangible assets	280,120	269,019
Investments in associates and joint ventures	1,808	1,656
Deferred tax assets	45,530	50,797
Other financial assets	94,961	91,361
Other non-current assets	9,179	9,169
Total non-current assets	739,816	725,221
Current assets		
Inventories	135,228	144,731
Trade and other receivables	332,639	324,044
Income tax receivable	2,710	2,461
Other financial assets	35,406	33,260
Other current assets	12,068	12,987
Cash and cash equivalents	391,374	373,015
Sub total	909,424	890,497
Assets held for sale	3,868	558
Total current assets	913,292	891,055
Total assets	1,653,108	1,616,276

(Millions of Yen)

	As of 31 March 2014	As of 30 June 2014
Equity and liabilities		
Equity		
Share capital	103,001	103,001
Capital surplus	176,822	176,822
Treasury shares	(54,535)	(59,115)
Retained earnings	864,830	844,590
Other components of equity	178,359	164,553
Total equity attributable to owners of the parent	1,268,476	1,229,850
Total equity	1,268,476	1,229,850
Liabilities		
Non-current liabilities		
Trade and other payables	64	72
Deferred tax liabilities	2	189
Retirement benefit liabilities	27,184	26,487
Provisions	4,264	4,247
Other financial liabilities	749	678
Other non-current liabilities	11,681	13,055
Total non-current liabilities	43,944	44,727
Current liabilities		
Trade and other payables	187,032	185,394
Income tax payable	13,237	9,836
Provisions	66,407	66,836
Other financial liabilities	1,062	3,032
Other current liabilities	72,950	76,601
Total current liabilities	340,688	341,699
Total liabilities	384,632	386,426
Total equity and liabilities	1,653,108	1,616,276

(4) Condensed Interim Consolidated Statements of Changes in Equity

(Millions of Yen)

	Equity attributable to owners of the parent					
					Other components of equity	
	Share capital	Capital surplus	Treasury shares	Retained earnings	Subscription rights to shares	Foreign currency translation adjustments
As of 1 April 2013	103,001	176,822	(72,285)	875,473	1,937	67,659
Comprehensive income						
Profit for the period	—	—	—	19,827	—	—
Other comprehensive income	—	—	—	—	—	32,152
Total comprehensive income	—	—	—	19,827	—	32,152
Transactions with owners of the parent						
Acquisition of treasury shares	—	—	(12)	—	—	—
Disposals of treasury shares	—	—	118	(23)	(44)	—
Cancellation of treasury shares	—	—	47,362	(47,362)	—	—
Dividends	—	—	—	(29,326)	—	—
Share-based payments	—	—	—	—	97	—
Transfers	—	—	—	1,942	—	—
Total transactions with owners of the parent	—	—	47,469	(74,770)	53	—
As of 30 June 2013	103,001	176,822	(24,816)	820,529	1,989	99,811

As of 1 April 2014	103,001	176,822	(54,535)	864,830	2,110	147,660
Comprehensive income						
Profit for the period	—	—	—	35,861	—	—
Other comprehensive income	—	—	—	—	—	(12,792)
Total comprehensive income	—	—	—	35,861	—	(12,792)
Transactions with owners of the parent						
Acquisition of treasury shares	—	—	(30,007)	—	—	—
Disposals of treasury shares	—	—	29	(5)	(15)	—
Cancellation of treasury shares	—	—	25,398	(25,398)	—	—
Dividends	—	—	—	(31,236)	—	—
Share-based payments	—	—	—	—	89	—
Transfers	—	—	—	537	—	—
Total transactions with owners of the parent	—	—	(4,581)	(56,102)	74	—
As of 30 June 2014	103,001	176,822	(59,115)	844,590	2,184	134,868

(Millions of Yen)

	Equity attributable to owners of the parent				Total equity
	Other components of equity			Total	
	Fair value movements on available-for-sale financial assets	Remeasurements of defined benefit plans	Total		
As of 1 April 2013	22,000	—	91,596	1,174,606	1,174,606
Comprehensive income					
Profit for the period	—	—	—	19,827	19,827
Other comprehensive income	2,119	1,942	36,213	36,213	36,213
Total comprehensive income	2,119	1,942	36,213	56,040	56,040
Transactions with owners of the parent					
Acquisition of treasury shares	—	—	—	(12)	(12)
Disposals of treasury shares	—	—	(44)	51	51
Cancellation of treasury shares	—	—	—	—	—
Dividends	—	—	—	(29,326)	(29,326)
Share-based payments	—	—	97	97	97
Transfers	—	(1,942)	(1,942)	—	—
Total transactions with owners of the parent	—	(1,942)	(1,889)	(29,190)	(29,190)
As of 30 June 2013	24,119	—	125,920	1,201,456	1,201,456
As of 1 April 2014	28,588	—	178,359	1,268,476	1,268,476
Comprehensive income					
Profit for the period	—	—	—	35,861	35,861
Other comprehensive income	(1,087)	537	(13,342)	(13,342)	(13,342)
Total comprehensive income	(1,087)	537	(13,342)	22,519	22,519
Transactions with owners of the parent					
Acquisition of treasury shares	—	—	—	(30,007)	(30,007)
Disposals of treasury shares	—	—	(15)	8	8
Cancellation of treasury shares	—	—	—	—	—
Dividends	—	—	—	(31,236)	(31,236)
Share-based payments	—	—	89	89	89
Transfers	—	(537)	(537)	—	—
Total transactions with owners of the parent	—	(537)	(464)	(61,146)	(61,146)
As of 30 June 2014	27,502	—	164,553	1,229,850	1,229,850

(5) Condensed Interim Consolidated Statements of Cash Flows

(Millions of Yen)

	Three months ended 30 June 2013	Three months ended 30 June 2014
Cash flows from operating activities		
Profit before tax	26,380	50,278
Depreciation and amortisation	15,676	15,453
Impairment losses and reversal of impairment losses	11,589	8,076
Finance income and expense	30	287
(Increase) decrease in inventories	(6,598)	(11,715)
(Increase) decrease in trade and other receivables	8,807	4,551
Increase (decrease) in trade and other payables	(18,323)	4,575
Other	18,341	11,542
Cash generated from operations	55,902	83,048
Income tax paid	(10,233)	(22,396)
Net cash flows from operating activities	45,669	60,653
Cash flows from investing activities		
Purchases of property, plant and equipment	(6,476)	(5,348)
Proceeds from sales of property, plant and equipment	372	3,327
Purchase of intangible assets	(7,504)	(11,519)
Purchase of available-for-sale financial assets	(202)	(34)
Proceeds from sales of available-for-sale financial assets	54	1,547
Interest and dividends received	922	1,211
Other	(762)	(1,331)
Net cash flows used in investing activities	(13,595)	(12,145)
Cash flows from financing activities		
Acquisition of treasury shares	(12)	(30,007)
Dividends paid to owners of the parent	(29,326)	(31,236)
Other	(80)	(189)
Net cash flows used in financing activities	(29,418)	(61,432)
Effect of exchange rate changes on cash and cash equivalents	11,520	(5,435)
Net increase (decrease) in cash and cash equivalents	14,175	(18,359)
Cash and cash equivalents at the beginning of the year	264,912	391,374
Cash and cash equivalents at the end of the period	279,087	373,015

(6) Notes on going concern assumption

Not applicable.

Supplement Documents for Results 1Q/FY2014 [IFRS]

Astellas Pharma Inc.

- Financial Results of 1Q/FY2014
- Pipeline list

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.

1. Consolidated Results (Full Basis)

Fiscal Year: From April through March

billion yen

	FY13 APR. - JUN.	FY14 APR. - JUN.	Change	Change (%)
Sales	269.5	295.2	25.7	9.5%
Cost of sales	81.2	76.0	-5.2	-6.4%
Ratio to Sales	30.1%	25.7%		
Gross profit	188.3	219.2	30.8	16.4%
SG&A expenses	91.1	96.9	5.8	6.3%
Ratio to Sales	33.8%	32.8%		
Advertising and Sales Promotion	24.5	28.2	3.7	15.1%
Personnel expenses	41.1	42.4	1.2	3.0%
Other	25.5	26.3	0.8	3.2%
R&D expenses	44.1	47.6	3.5	8.0%
Ratio to Sales	16.4%	16.1%		
Amortisation of intangible assets	8.8	8.9	0.1	0.8%
Share of profits of associates and joint ventures	0.2	0.2	-0.0	-1.6%
Other income	0.1	2.7	2.6	-
Gain on sales of property, plant and equipment	0.0	0.0	0.0	27.9%
Net foreign exchange gains	-	2.5	2.5	-
Other expense	18.2	18.1	-0.1	-0.6%
Loss on sales and disposal of property, plant and equipment	0.1	0.2	0.0	20.2%
Impairment losses	11.6	8.1	-3.5	-30.3%
Restructuring costs	4.7	9.3	4.6	99.5%
Net foreign exchange losses	1.7	-	-1.7	-
Operating profit	26.4	50.6	24.2	91.5%
Ratio to Sales	9.8%	17.1%		
Finance income	0.6	1.8	1.2	183.5%
Gain on sales of available-for-sale financial assets	0.0	0.9	0.8	-
Finance expense	0.7	2.1	1.4	213.3%
Impairment losses for available-for-sale financial assets	0.6	2.0	1.4	220.1%
Profit before tax	26.4	50.3	23.9	90.6%
Ratio to Sales	9.8%	17.0%		
Income tax expense	6.6	14.4	7.9	120.0%
Profit for the period	19.8	35.9	16.0	80.9%
Ratio to Sales	7.4%	12.1%		
Comprehensive income for the period	56.0	22.5	-33.5	-59.8%

2. Consolidated Results (Core Basis)

billion yen

	FY13 APR. - JUN.	FY14 APR. - JUN.	Change	Change (%)	Forecasts FY14 Full Year	Change from FY13 Change (%)
Sales	269.5	295.2	25.7	9.5%	1,192.0	4.6%
Cost of sales	81.2	76.0	-5.2	-6.4%		
Ratio to Sales	30.1%	25.7%				
Gross profit	188.3	219.2	30.8	16.4%		
SG&A expenses	91.1	96.9	5.8	6.3%		
Ratio to Sales	33.8%	32.8%				
Advertising and Sales Promotion	24.5	28.2	3.7	15.1%		
Personnel expenses	41.1	42.4	1.2	3.0%		
Other	25.5	26.3	0.8	3.2%		
R&D expenses	44.1	47.6	3.5	8.0%	198.0	3.4%
Ratio to Sales	16.4%	16.1%			16.6%	
Amortisation of intangible assets	8.8	8.9	0.1	0.8%		
Share of profits of associates and joint ventures	0.2	0.2	-0.0	-1.6%		
Operating profit	44.5	66.0	21.5	48.2%	208.0	11.7%
Ratio to Sales	16.5%	22.4%			17.4%	
Finance income	0.6	1.0	0.3	55.6%		
Finance expense	0.0	0.1	0.1	112.4%		
Profit before Tax	45.1	66.8	21.8	48.3%		
Ratio to Sales	16.7%	22.6%				
Income tax expense	13.3	20.4	7.1	53.3%		
Profit for the period	31.8	46.4	14.7	46.2%	154.0	16.0%
Ratio to Sales	11.8%	15.7%			12.9%	

3. Exchange Rate

yen

	FY13 APR. - JUN.Ave.	FY14 APR. - JUN.Ave.	FY13 End	FY14 1Q End	Forecasts FY14 Full Year
Yen/USD	99	102	103	101	100
Yen/EUR	129	140	142	138	140

∗ Exchange rate fluctuations had positive impact by 10.0 billion yen on sales and positive impact by 8.3 billion yen on Core operating profit in Q1/FY2014

4. Reconciliation of Full Basis to Core Basis

Fiscal Year: From April through March

Billion yen

Account item	FY13 APR. - JUN.			FY14 APR. - JUN.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	**269.5**	**-**	**269.5**	**295.2**	**-**	**295.2**
Cost of sales	81.2	-	81.2	76.0	-	76.0
Gross profit	**188.3**	**-**	**188.3**	**219.2**	**-**	**219.2**
SG&A expenses	91.1	-	91.1	96.9	-	96.9
R&D expenses	44.1	-	44.1	47.6	-	47.6
Amortisation of intangible assets	8.8	-	8.8	8.9	-	8.9
Share of profits of associates and joint ventures	0.2	-	0.2	0.2	-	0.2
Other income *1	0.1	-0.1	-	2.7	-2.7	-
Other expense *1	18.2	-18.2	-	18.1	-18.1	-
Operating profit	**26.4**	**18.1**	**44.5**	**50.6**	**15.4**	**66.0**
Finance income *2	0.6	-0.0	0.6	1.8	-0.9	1.0
Finance expense *2	0.7	-0.6	0.0	2.1	-2.0	0.1
Profit before tax	**26.4**	**18.7**	**45.1**	**50.3**	**16.6**	**66.8**
Income tax expense	6.6	6.8	13.3	14.4	6.0	20.4
Profit for the period	**19.8**	**11.9**	**31.8**	**35.9**	**10.5**	**46.4**

*1. “Other income” and “Other expense” are excluded from Core results.
“Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses for other intangible assets, loss on the restructuring, and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Core results as non-core items.

5. Segment Information by Region

billion yen

		FY13 APR. - JUN.	FY14 APR. - JUN.	Change	Change (%)	Forecasts FY14 Full Year	Change from FY13 Change (%)
Sales		269.5	295.2	25.7	9.5%	1,192.0	4.6%
	Japan	124.7	112.8	-11.9	-9.5%	528.4	-0.4%
	Ratio to Sales	46.3%	38.2%			44.3%	
	Americas	68.8	83.8	15.1	21.9%	289.2	0.8%
	Ratio to Sales	25.5%	28.4%			24.3%	
	Europe	62.1	82.4	20.4	32.9%	305.6	15.6%
	Ratio to Sales	23.0%	27.9%			25.6%	
	Asia and Oceania	13.9	16.1	2.1	15.1%	68.7	18.6%
	Ratio to Sales	5.2%	5.4%			5.8%	

- Calculated according to locations of sellers.
- Europe: Including Middle and Near East and Africa

6. Depreciation/Amortisation

billion yen

		FY13 APR. - JUN.	FY14 APR. - JUN.	Change	Change (%)	Forecasts FY14 Full Year	Change from FY13 Change (%)
Depreciation(Tangible)							
	Consolidated	5.7	5.3	-0.4	-7.1%	23.0	-0.8%
Amortisation(Intangible) *							
	Consolidated	10.0	10.2	0.2	1.8%	42.0	2.1%

* Amortisation(Intangible): Including amortisation of software, etc.

7. Sales of major products

1)Sales of global products

billion yen

	FY13 APR. - JUN.	FY14 APR. - JUN.	Change	Change (%)	Forecasts FY14 Full Year	Change from FY13 Change (%)
Prograf	44.1	47.0	2.9	6.6%	181.3	0.1%
Sales by Astellas	42.9	46.2	3.3	7.6%	177.6	1.0%
Japan (Including Graceptor)	12.6	11.4	-1.1	-8.9%	49.6	-1.5%
Americas	7.2	8.8	1.6	22.1%	27.4	-7.5%
Europe	17.1	18.6	1.6	9.2%	71.4	0.8%
Advagraf	5.6	6.6	1.0	18.8%		
Asia and Oceania	6.0	7.3	1.2	20.5%	29.2	16.9%
Exports to third parties	1.2	0.9	-0.4	-29.2%	3.7	-29.2%
Harnal	15.3	13.7	-1.6	-10.2%	55.9	-6.0%
Sales by Astellas	13.9	12.5	-1.4	-10.2%	52.0	-5.8%
Japan	5.1	3.9	-1.2	-24.3%	16.0	-20.9%
Europe	5.1	4.5	-0.5	-10.5%	18.7	-3.6%
Asia and Oceania	3.6	4.0	0.4	11.5%	16.8	12.3%
Bulk and Royalties	1.3	1.2	-0.1	-9.6%	4.0	-7.9%
Vesicare	31.6	33.0	1.4	4.4%	120.7	-9.8%
Japan	7.0	5.3	-1.8	-25.0%	24.2	-21.1%
Americas	13.4	15.5	2.1	15.6%	48.2	-17.0%
Europe	10.1	11.0	0.8	8.3%	42.9	5.3%
Asia and Oceania	0.9	1.2	0.2	22.6%	4.8	26.3%
Betanis/Myrbetriq/BETMIGA	4.7	10.7	6.0	128.2%	56.4	100.0%
Japan	2.4	2.7	0.3	12.2%	20.9	80.3%
Americas	2.1	6.2	4.0	187.3%	25.9	78.3%
Europe	0.2	1.8	1.7	-	9.3	349.5%
Funguard/MYCAMINE	8.3	8.9	0.6	6.7%	36.8	2.0%
Japan	2.8	2.5	-0.3	-10.2%	11.4	-7.2%
Americas	2.8	2.8	0.0	0.7%	10.9	-7.6%
Europe	2.0	2.7	0.7	34.0%	10.1	17.6%
Asia and Oceania	0.7	0.9	0.1	21.1%	4.4	29.2%
Protopic	6.1	6.0	-0.1	-1.2%	19.7	-21.3%
Americas	2.9	3.1	0.2	8.6%	8.4	-27.6%
Europe	1.6	2.1	0.5	29.5%	7.4	5.4%
Asia and Oceania	0.7	0.8	0.1	14.1%	3.6	39.5%
XTANDI	8.5	23.4	14.9	174.6%		
US	8.1	14.7	6.5	80.4%	56.0	26.5%
ex-US	0.4	8.7	8.3	-		
Japan	-	1.5	1.5	-		
Americas (ex-US)	0.0	0.4	0.4	-		
Europe	0.4	6.7	6.3	-	26.6	181.4%
Asia and Oceania	-	0.0	0.0	-		
Eligard	4.6	5.1	0.4	9.5%		
Europe	4.6	5.1	0.4	9.4%	20.9	14.1%
Asia and Oceania	0.0	0.0	0.0	-		

- Sales of products in Japan are shown in a gross sales basis.
- Europe: Including Middle and Near East and Africa

2)Sales of products in Japan

billion yen

<Global products>	FY13 APR. - JUN.	FY14 APR. - JUN.	Change	Change (%)	Forecasts FY14 Full Year	Change from FY13 Change (%)
Prograf （Including Graceptor）	12.6	11.4	-1.1	-8.9%	49.6	-1.5%
Harnal	5.1	3.9	-1.2	-24.3%	16.0	-20.9%
Vesicare	7.0	5.3	-1.8	-25.0%	24.2	-21.1%
Betanis	2.4	2.7	0.3	12.2%	20.9	80.3%
Funguard	2.8	2.5	-0.3	-10.2%	11.4	-7.2%
XTANDI	-	1.5	1.5	-		
<Domestic products>						
Lipitor [Family]	15.7	12.1	-3.6	-22.8%	52.6	-15.7%
Caduet	2.6	2.6	-0.0	-0.6%		
Micardis [Family]	23.7	23.3	-0.4	-1.6%	97.5	-0.1%
Micombi	2.9	2.7	-0.2	-6.8%		
Micamlo	5.4	5.7	0.3	6.1%		
Gaster	6.6	4.8	-1.8	-27.5%	19.5	-24.2%
Myslee	7.0	4.8	-2.1	-30.8%	20.2	-28.5%
Seroquel	5.2	3.4	-1.8	-34.7%	12.6	-35.6%
Vaccines	4.8	5.3	0.5	10.1%	35.7	2.2%
Cefzon	1.5	1.2	-0.3	-18.9%	5.3	-16.9%
Celecox	9.9	8.4	-1.6	-15.7%	45.9	3.6%
Geninax	2.9	2.3	-0.6	-20.9%	12.4	5.1%
Bonoteo	3.1	2.6	-0.5	-14.9%	14.7	4.0%
Symbicort	7.6	6.2	-1.3	-17.5%	36.3	1.9%
Argamate	1.5	1.5	-0.1	-3.8%	6.4	5.6%
Kiklin	0.3	0.3	0.0	14.7%	2.1	44.5%
Gonax	0.5	0.8	0.3	63.9%	4.8	90.0%
Cimzia	0.6	1.1	0.6	95.4%	12.3	279.4%
Suglat	-	2.5	2.5	-		
Total Rx Sales In Japan	121.1	109.0	-12.0	-9.9%	508.3	-1.4%

- Sales of products in Japan are shown in a gross sales basis.

3)Sales of products in Americas and Europe

billion yen

	FY13 APR. - JUN.	FY14 APR. - JUN.	Change	Change (%)	Forecasts FY14 Full Year	Change from FY13 Change (%)
Scan* (Americas)	17.1	16.6	-0.5	-3.0%	53.3	-13.8%
Lexiscan	15.8	16.5	0.7	4.6%		
AmBisome (Americas)	1.9	1.9	-0.0	-1.9%	8.0	-1.0%
Tarceva	12.2	13.6	1.4	11.6%		
(US)	8.1	9.6	1.5	18.8%		
(ex-US)	4.0	3.9	-0.1	-2.7%		
Qutenza (Europe)	0.3	0.4	0.1	35.3%		
DIFICLIR (Europe)	0.2	0.5	0.2	92.9%		

* Adenoscan + Lexiscan

4)Sales in Americas and Europe(Local currency)

Unit:M$

Americas	FY13 APR. - JUN.	FY14 APR. - JUN.	Change	Change (%)	Forecasts FY14 Full Year	Change from FY13 Change (%)
Net Sales	697	821	124	17.8%	2,892	1.0%
Prograf	73	86	13	18.1%	274	-7.3%
Scan*	174	163	-11	-6.2%	533	-13.6%
Lexiscan	160	161	2	1.1%		
AmBisome	20	19	-1	-5.2%	80	-0.8%
Protopic	29	31	1	5.0%	84	-27.4%
VESIcare	136	152	16	11.8%	482	-16.8%
Myrbetriq	22	60	39	177.7%	259	78.8%
MYCAMINE	28	28	-1	-2.7%	109	-7.4%
Tarceva	123	133	10	7.9%		
US	82	94	12	14.8%		
ex-US	41	38	-2	-6.0%		
XTANDI	82	148	65	79.2%		
US	82	144	61	74.4%	560	26.8%
Americas (ex-US)	0	4	4	-		

* Adenoscan + Lexiscan

Unit:M€

Europe	FY13 APR. - JUN.	FY14 APR. - JUN.	Change	Change (%)	Forecasts FY14 Full Year	Change from FY13 Change (%)
Net Sales	481	589	107	22.3%	2,183	11.0%
Harnal (Omnic)	50	41	-9	-17.4%	162	-8.3%
Sales by Astellas	39	32	-7	-17.6%	133	-7.5%
Capsule	18	16	-2	-10.6%	66	-3.4%
OCAS	21	16	-5	-23.4%	67	-11.3%
Bulk and Royalties	10	9	-2	-16.8%	29	-11.6%
Prograf	142	139	-3	-1.8%	536	-5.1%
Sales by Astellas	132	133	1	0.5%	510	-3.3%
Advagraf	43	47	4	9.4%		
Exports to third parties	10	6	-3	-34.2%	26	-31.1%
Vesicare	79	78	-0	-0.3%	307	1.1%
BETMIGA	1	13	12	-	66	331.4%
Protopic	13	15	2	19.2%	53	1.2%
MYCAMINE	15	19	4	23.4%	72	12.8%
Eligard	36	36	0	0.7%	149	9.6%
Qutenza	3	3	1	24.5%		
DIFICLIR	2	3	1	77.6%		
XTANDI	3	48	45	-	190	170.0%

- Europe: Including Middle and Near East and Africa

8.Consolidated statements of financial position

Billion yen

			31-Mar-14	30-Jun-14	
			Amount	Amount	Change
Assets			**1,653.1**	**1,616.3**	**-36.8**
	Non-current assets		**739.8**	**725.2**	**-14.6**
		Property, plant and equipment	191.5	188.2	-3.2
		Goodwill	116.8	115.0	-1.8
		Other intangible assets	280.1	269.0	-11.1
		Investments in associates and joint ventures	1.8	1.7	-0.2
		Deferred tax assets	45.5	50.8	5.3
		Other financial assets	95.0	91.4	-3.6
		Other non-current assets	9.2	9.2	-0.0
	Current assets		**913.3**	**891.1**	**-22.2**
		Inventories	135.2	144.7	9.5
		Trade and other receivables	332.6	324.0	-8.6
		Income tax receivable	2.7	2.5	-0.2
		Other financial assets	35.4	33.3	-2.1
		Other current assets	12.1	13.0	0.9
		Cash and cash equivalents	391.4	373.0	-18.4
		Assets held for sale	3.9	0.6	-3.3

Billion yen

	31-Mar-14	30-Jun-14	
	Amount	Amount	Change
Equity and Liabilities	**1,653.1**	**1,616.3**	**-36.8**
Equity	**1,268.5**	**1,229.8**	**-38.6**
Equity attributable to owners of the parent	**1,268.5**	**1,229.8**	**-38.6**
Share capital	103.0	103.0	-
Capital surplus	176.8	176.8	-
Treasury shares	-54.5	-59.1	-4.6
Retained earnings	864.8	844.6	-20.2
Other components of equity	178.4	164.6	-13.8
Liabilities	**384.6**	**386.4**	**1.8**
Non-current liabilities	**43.9**	**44.7**	**0.8**
Trade and other payables	0.1	0.1	0.0
Deferred tax liabilities	0.0	0.2	0.2
Retirement benefit liabilities	27.2	26.5	-0.7
Provisions	4.3	4.2	-0.0
Other financial liabilities	0.7	0.7	-0.1
Other non-current liabilities	11.7	13.1	1.4
Current liabilities	**340.7**	**341.7**	**1.0**
Trade and other payables	187.0	185.4	-1.6
Income tax payable	13.2	9.8	-3.4
Provisions	66.4	66.8	0.4
Other financial liabilities	1.1	3.0	2.0
Other current liabilities	73.0	76.6	3.7

R&D Pipeline (August 2014)

1. Global Development

(1) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin*	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer in patients who have not received chemotherapy	US Filed (Mar. 2014) Europe Filed (Apr. 2014) Japan Phase-III Asia Phase-III	Oral	Medivation	New indication
		Non-metastatic castration-resistant prostate cancer	US Phase-III Europe Phase-III Asia Phase-III			New indication
		Breast cancer	US/Europe Phase-II			New indication

*"In-house" shown in the "origin" column includes discovery by collaborative research. (The same applicable hereafter.)

(2) Phase-III / Phase-II (1/2)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
erlotinib	HER1/EGFR tyrosine kinase inhibitor	Pediatric ependymoma	US Phase-III	Oral	In-house (co-development with Roche/Genentech)	Not a new indication, rather a supplement whose results are planned to submit to the FDA
ASP0113 (VCL-CB01)	DNA vaccine for cytomegalovirus	Cytomegalovirus reactivation in hematopoietic cell transplant recipients	US/Europe/Japan Phase-III	Injection	Vical	
		Cytomegalovirus infection or reactivation in solid organ transplant recipients	US/Europe Phase-II			
YM905 solifenacin	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	US/Europe Phase-III	Oral	In-house	New indication (pediatric)
EB178 solifenacin/ mirabegron	Concomitant use of solifenacin and mirabegron	Urinary frequency, urinary incontinence or urgency associated with overactive bladder	Europe/US/Asia Phase-III	Oral	In-house	
fidaxomicin	Macrocyclic antibiotic	Infectious enteritis (bacterial target: *Clostridium difficile*)	Japan Phase-III	Oral	Cubist	
		Clostridium difficile infection in pediatric patients	Europe Phase-III			New indication (pediatric)
ASP015K	JAK inhibitor	Rheumatoid arthritis	Japan Phase-III (US/Europe Phase-II*)	Oral	In-house	

*A license agreement was executed with Janssen Biotech, Inc. for the development and commercialization worldwide except for Japan.
Phase-IIb studies were completed by Astellas.

(2) Phase-III / Phase-II (2/2)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP1517 (FG-4592) roxadustat	HIF stabilizer	Anemia associated with chronic kidney disease in patients not on dialysis and on dialysis	Europe Phase-III Japan Phase-II	Oral	FibroGen	
YM311 (FG-2216)	HIF stabilizer	Renal anemia	Europe Phase-II Japan Phase-I	Oral	FibroGen	
ASKP1240	Anti-CD40 monoclonal antibody	Prevention of organ transplant rejection	US Phase-II Japan Phase-I	Injection	Kyowa Hakko Kirin	
ASP3652	Inhibition of afferent nerve activity	Bladder pain syndrome / Interstitial cystitis	Europe Phase-II Japan Phase-I	Oral	In-house	
ASP1707	GnRH antagonist	Endometriosis	Europe/Japan Phase-II	Oral	In-house	
		Prostate cancer	Europe Phase-I			
ASP4901 (AKP-002)	PDE9 inhibitor	Lower urinary tract symptoms associated with benign prostatic hyperplasia	Japan Phase-II	Oral	ASKA	
ASP8477	Inhibition of central sensitization	Neuropathic pain	Europe Phase-II	Oral	In-house	

2. Local Development: Japan

(1) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP7374	Influenza vaccine	Prophylaxis of seasonal influenza	Japan Filed (May 2014)	Injection	UMN Pharma	
certolizumab pegol	PEGylated anti-tumor necrosis factor-alpha antibody	Disease modifying anti-rheumatic drugs (DMARD)-naive rheumatoid arthritis	Japan Filed (Jun. 2014)	Injection	UCB	New indication
nateglinide	Fast acting insulin secretion enhancer	Type 2 diabetes Combination with DPP-4 inhibitor	Japan Filed (Jul. 2014)	Oral	Ajinomoto Pharmaceuticals	New indication
YM060 ramosetron	5-HT3 receptor antagonist	Irritable bowel syndrome with diarrhea in female patients	Japan Filed (Jul. 2014)	Oral	In-house	New indication

(2) Phase-III / Phase-II

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
YM533 beraprost sodium	Prostacyclin receptor stimulator	Chronic renal failure (primary, nephrosclerosis)	Japan/Asia Phase-III	Oral	Toray	New indication
FK949E quetiapine	Serotonin/dopamine antagonist	Depressive episode in bipolar disorders	Japan Phase-III	Oral	AstraZeneca	New indication New formulation
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients not on dialysis with chronic kidney disease	Japan Phase-III	Oral	Amgen	New indication
		Hyperphosphatemia in patients on dialysis with chronic kidney disease (granule formulation)	Japan Bioequivalence study	Oral		New formulation
ASP3550 degarelix	GnRH antagonist	Prostate cancer (three-month formulation)	Japan Phase-III	Injection	Ferring	New formulation
AMG 785 romosozumab	Anti-Sclerostin monoclonal antibody	Osteoporosis	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
AMG 145 evolocumab	Anti-PCSK-9 monoclonal antibody	Hyperlipidemia	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
AMG 102 rilotumumab	Anti-HGF monoclonal antibody	Gastric cancer	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
ASP7373	Influenza vaccine	Prophylaxis of H5N1 influenza	Japan Phase-II	Injection	UMN Pharma	
ASP0456 linaclotide	Guanylate cyclase type-C receptor agonist	Irritable bowel syndrome	Japan Phase-II	Oral	Ironwood	
ASP7991	Calcium-sensing receptor activator	Secondary hyperparathyroidism	Japan Phase-II	Oral	In-house	

3. Local Development: Europe

(1) Phase-lll / Phase-ll

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
NGX-4010 capsaicin	TRPV1 agonist	Peripheral diabetic neuropathy	Europe Phase-III	Patch	NeurogesX	New indication

4. Local Development: US

(1) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
isavuconazole	Azole antifungal	Invasive aspergillosis and invasive mucormycosis	US Filed (Jul. 2014)	Injection Oral	Basilea	
		Candidemia / Invasive candidiasis	US Phase-III			

5. Phase-I

Code No. Generic Name	Target Disease	Dosage Form	Origin
AGS-16M8F/ AGS-16C3F	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASG-22ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASP9226	Neuropathic pain	Oral	In-house
ASP8232	Diabetic nephropathy	Oral	In-house
ASP3662	Alzheimer's disease	Oral	In-house
ASG-15ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASP2215	Cancer	Oral	In-house
ASP3325	Hyperphosphatemia	Oral	In-house
CK-2127107	Skeletal muscle disease (non-neuromuscular indications)	Oral	Cytokinetics
ASP5878	Cancer	Oral	In-house
AMG 337	Gastric cancer	Oral	Amgen (co-development with Amgen Astellas)
ASP8273	Cancer	Oral	In-house
ASP7962	Osteoarthritis, Chronic low back pain	Oral	In-house
YM178 mirabegron	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	Oral	In-house
ASP7657	Diabetic nephropathy	Oral	In-house
ASP3700	Osteoarthritis	Oral	In-house
AGS67E	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASP5633	Stress urinary incontinence	Oral	In-house

<Changes from the Previous Announcement on May 12, 2014> (Changed underlined items)

Launched

-Enzalutamide: Removed the previous item below. It was launched in Japan in May 2014.

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Origin	Remarks
MDV3100 enzalutamide	XTANDI (Mar. 2014)	Androgen receptor inhibitor	Castration-resistant prostate cancer*	Japan	Oral	Medivation	

*Precautions regarding indication include the description that the efficacy and safety of the drug have not been established in patients with prostate cancer who have not received chemotherapy.

Filed

-ASP7374: Filed in Japan.

-Certolizumab pegol: Filed in Japan.

-Nateglinide: Filed in Japan.

-Ramosetron: Filed in Japan.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP7374	Influenza vaccine	Prophylaxis of seasonal influenza	Japan Filed (May 2014)	Injection	UMN Pharma	
certolizumab pegol	PEGylated anti-tumor necrosis factor-alpha antibody	Disease modifying anti-rheumatic drugs (DMARD)-naive rheumatoid arthritis	Japan Filed (Jun. 2014)	Injection	UCB	New indication
nateglinide	Fast acting insulin secretion enhancer	Type 2 diabetes Combination with DPP-4 inhibitor	Japan Filed (Jul. 2014)	Oral	Ajinomoto Pharmaceuticals	New indication
YM060 ramosetron	5-HT3 receptor antagonist	Irritable bowel syndrome with diarrhea in female patients	Japan Filed (Jul. 2014)	Oral	In-house	New indication

-Isavuconazole: Filed in the US.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
isavuconazole	Azole antifungal	Invasive aspergillosis and invasive mucormycosis	US Filed (Jul. 2014)	Injection Oral	Basilea	

Phase-III / Phase-II

-Fidaxomicin: Entered into Phase-III in Europe for pediatric indication.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
fidaxomicin	Macrocyclic antibiotic	*Clostridium difficile* infection in pediatric patients	Europe Phase-III	Oral	Cubist	New indication (pediatric)

-ASP015K: Entered into Phase-III in Japan.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP015K	JAK inhibitor	Rheumatoid arthritis	Japan Phase-III (US/Europe Phase-II*)	Oral	In-house	

*A license agreement was executed with Janssen Biotech, Inc. for the development and commercialization worldwide except for Japan.
Phase-IIb studies were completed by Astellas.

Phase-I

-ASP5633 [Stress urinary incontinence]: Entered into Phase-I.